Indaptus Therapeutics (INDP) to Announce Earnings on Monday

Key Points

• Indaptus Therapeutics is expected to report Q2 2026 results before the market opens Monday, August 17, with analysts forecasting a loss of $1.57 per share. The earnings call is scheduled for August 21 at 9:30 a.m. ET.
• The company previously reported a quarterly loss of $0.23 per share, beating consensus estimates for a $1.87 loss.
• INDP shares opened at $1.18, well below their 50-day and 200-day moving averages, while analysts maintain an overall “Sell” rating and institutional investors own 7.06% of the stock.

Indaptus Therapeutics (NASDAQ:INDP - Get Free Report) is expected to be releasing its Q2 2026 results before the market opens on Monday, August 17th. Analysts expect Indaptus Therapeutics to post earnings of ($1.57) per share for the quarter. Investors can check the company's upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Friday, August 21, 2026 at 9:30 AM ET.

Indaptus Therapeutics (NASDAQ:INDP - Get Free Report) last issued its quarterly earnings results on Friday, May 15th. The company reported ($0.23) EPS for the quarter, beating analysts' consensus estimates of ($1.87) by $1.64.

Indaptus Therapeutics Stock Performance

Shares of INDP opened at $1.18 on Monday. The business has a 50-day moving average of $2.70 and a 200 day moving average of $2.27. Indaptus Therapeutics has a fifty-two week low of $0.92 and a fifty-two week high of $8.69. The firm has a market cap of $133.62 million, a P/E ratio of -0.08 and a beta of 1.18.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Indaptus Therapeutics stock. Virtu Financial LLC bought a new stake in Indaptus Therapeutics, Inc. (NASDAQ:INDP - Free Report) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 18,997 shares of the company's stock, valued at approximately $55,000. Virtu Financial LLC owned approximately 1.72% of Indaptus Therapeutics at the end of the most recent reporting period. Hedge funds and other institutional investors own 7.06% of the company's stock.

Analysts Set New Price Targets

Several equities research analysts have commented on INDP shares. Wall Street Zen raised shares of Indaptus Therapeutics to a "hold" rating in a report on Saturday, June 27th. Weiss Ratings reiterated a "sell (e+)" rating on shares of Indaptus Therapeutics in a research note on Friday, July 17th. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company has an average rating of "Sell".

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company's Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus' pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source